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Abstract
Blood-brain barrier breakdown occurring in glioblastoma is a temporary condition often 
denounced by contrast enhancement upon neurological examination. This condition is 
useful to increase the intracranial concentration of anti-cancer drugs. The prognosis of glio-
blastoma and its resistance to conventional therapy has stimulated interest in the search of 
biomarkers able to unmask and monitor brain barrier breakdown to calibrate the treatment. 
Despite numerous studies had evidenced the role of circulating tumor and endothelial cells 
to monitor brain tumor, the mechanism of tumor cells release in the bloodstream and its 
prognostic significance remain unclear. In this chapter, we want to furnish an update on 
the relationship between the vascular damage occurring during glioblastoma disease and  
the reactivity of innate immunity focusing on the cytokines network. Our aim is answer to the  
question: when and why the liquid biopsy is useful in glioblastoma disease.
Keywords: blood-brain barrier, glioblastoma, liquid biopsy, circulating tumor cells, 
circulating endothelial cells
1. Introduction
Gliomas are associated with aggressive invasion of the surrounding brain parenchyma. The 
invasion is due to a combination of transformed cells phenotype changes, innate and acquired 
immunity and autocrine and paracrine release of growing and permeabilizing chemokines. 
This intricate scenario develops within the cerebral parenchyma, notoriously protected by an 
ultraspecialized system. Several experimental models of glioma, have been used in vivo to 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
monitor the infiltration of tumor cells in the parenchyma and/or perivascular spaces, even at a 
single cell level [1–3]. However, the relationship between glioma-induced BBB dysregulation 
and glioma invasion remains poorly understood. In this chapter we review the natural history 
of glioblastoma and, on the basis of the scientific evidence published to date, we try to give 
an explanation and meaning to biomarkers found in the peripheral blood. In particular, we 
focus our attention on cellular biomarkers, the circulating tumor cells and cellular endothelial 
progenitors. Our interest is aimed at giving an order in the context of human cell biology of 
human glioblastoma. This intracranial tumor remains today one of the big killers and repre-
sents a major challenge in the field of oncology because it is unresponsive to treatment and 
able to progress in a way difficult to monitor.
2. Development and structure of the blood-brain barrier
Blood-brain barrier (BBB) separates in a selective manner the nerve tissue of the central ner-
vous system (CNS) from the blood. It is present throughout the CNS, except in the circumven-
triculars organs, where the capillaries are fenestrated as occurs in choroid plexuses. Indeed, 
such an anatomical membrane can selectively transport, through the capillary wall, large 
(>500 Da) or water soluble (hydrophilic) substances, whereas, small, lipid-soluble (hydropho-
bic) substances can freely pass the endothelium by passive diffusion [4, 5].
Classically, BBB was recognized as the structural base of the so-called immune privilege of the 
brain. Thereby, antigens would be sequestered within the brain and would be invisible to the 
immune system [6].
This view has been challenged in recent years, due to the discovery of the so-called “glym-
phatic system” (GS) and of meningeal lymphatics (MLs) of dura mater. GS allow that cerebro-
spinal fluid flows into brain within periarterial spaces and interstitial fluid and solute clear via 
perivenous spaces. Furtherly, MLs follow dural blood vessels and cranial nerves and exit the 
cranium via the foramina together with the venous sinuses, arteries, and cranial nerves in order 
to join cervical lymph nodes. The relationship of this system with the equilibrium of the blood-
brain barrier is unknown and its role in human pathology has yet to be clarified (Figure 1) [6].
Tight junctions (TJs) between endothelial cells (ECs) are the main component of BBB. TJs are 
occluding cell junctions, which act to seal off the intercellular space and consist of transmem-
brane proteins such as occludins (Oclns) and claudins (Cldns), connected intracellularly to the 
actin filaments, forming strands in the plasma membrane.
TJs blocks the intercellular pathway and forms a barrier between the arterial blood and the 
nervous tissue, regulated by the end feet of astrocytes that cover the basement membrane of 
the capillaries [5].
The development of the BBB begins with angiogenesis, started from invasion of the neuro-
ectoderm by endothelial progenitor cells from pre-existing vessels. The endothelia of these 
vascular sprouts show many characteristics of mature BBB such as TJs, transcytotic vesicles, 
nutrient transporters and leukocyte adhesion molecules. Afterwards, contact with CNS cells 
and pericytes (PCs) allows the full functional maturation of the membrane separating nervous 
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tissue from blood. TJs are elaborated and sealed, transcytosis decreases, leukocyte adhesion 
molecules are downregulated and efflux transporter expression increases [7].
Vascular endothelial growth factor (VEGF), VEGFR-2 and its ligand, play a pivotal role in embry-
onic angiogenesis and vasculogenesis [8]. In the developing CNS, embryonic brain cells of the 
subventricular neuroectoderm synthetize VEGF that directs angiogenesis via a concentration 
gradient through the angiogenic sprouting from vessel networks outside the CNS, in particular, 
the perineural vascular plexus (PNVP). Within the brain, blood vessels furtherly, then, generate 
huge networks as the neural tissue grows and concomitantly remodel into a vascular tree with 
arterial and venous hierarchy [9, 10]. Such a process, when VEGF is reduced or absent, develops 
in an incorrect way generating decreased blood vessel branching and density in the cortex [11].
Vasculogenesis and angiogenesis have been extensively studied in experimental setting in 
mouse retina and hindbrain and in zebrafish with the development of the “tip-stalk” model 
of angiogenic sprouting, which describes the different precursor of endothelial cells within 
newly formed vascular sprouts:
1. Tip cells drive the sprouting, migrating and extending filopodia that scan the environment 
for signals that can act as guides for vascular growth.
2. Behind the tip cells, another group of elements, termed stalk cells, proliferate and form the 
nascent vascular lumen.
Once mature connections and blood flow have been established, the proliferation and the 
migration of “activate endothelium” ceases. Tip and stalk cells display differential gene 
expression profiles [12]. The Notch signaling pathway is a very important tool in the regulation 
Figure 1. Blood-brain barrier components and their interactions (figure partially modified from Hawkins BT and Davis 
TP [105]).
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of the tip and stalk cells specification. The activation of Notch signaling inhibits tip cells dif-
ferentiation and promotes the stalk cell phenotype [13].
Wingless-type mouse mammary tumor virus (MMTV) integration site family (Wnt) pathway 
plays a pivotal role in angiogenesis both physiological and pathological and in vessels remod-
eling [14, 15]. Three Wnt signaling pathways are known: the so-called “canonical” Wnt/β-
catenin and the two “noncanonical” pathways: the Wnt/calcium (Wnt/Ca2+) and the Wnt/
planar cell polarity (Wnt/PCP) [16].
The canonical Wnt/β-catenin signaling pathway targets the regulatory molecule β-catenin. The 
so-called cytoplasmic destruction complex, consisting of glycogen synthase kinase-3β (GSK3β), 
Axin, Casein kinase1/2 (CK1/2), Protein phosphatase 2A (PP2A), and adenomatous polyposis 
coli (APC) leads to a post-translational modification status of β-catenin. In the absence of Wnt 
signaling, cytosolic β-catenin is phosphorylated by CK1 at Thr41, and GSK3β at Ser33 and 
Ser37. Phosphorylated β-catenin is then ubiquitinated via the E3 ligase, β-transducing-repeat-
containing protein (β-TrCP), and thereby prepared for proteasomal degradation. Conversely, 
Wnt binding to Frizzled proteins, a Wnt receptors family recruits the co-receptor LRP5/6, 
that causes an activation of the cytoplasmic phosphoprotein Disheveled. These events lead to 
the inhibition of GSK3β, thereby promoting the accumulation of unphosphorylated β-catenin 
and its subsequent translocation to the nucleus, where it binds to a variety of transcription 
factors, including T-cell factor/lymphocyte enhancing factor (TCF/LEF) and forkhead box (in 
particular, the FOXO subtypes) family proteins. TCF/LEF represses targets in the absence of 
signaling, but beta-catenin, when its pathway is activated, enters into the nucleus, binds to 
TCF on the chromatin and allows the transcription of a number of Wnt target genes involved 
in cell proliferation, Wnt signal transduction and vascular growth [17, 18].
Tight junctions are organized to form a paracellular seal in transporting epithelia in order to 
allow the directional transfer of ions and solutes across cell layers.
Tight junctions comprise several trans-membrane proteins (TMPs) which interact with adaptor 
proteins of the cytoplasmic plaque via their C-terminal domains. TMPs are classified on the basis 
of their number of transmembrane domains (tetraspan, trispan, and single-span domains) and 
include the tetraspan Marvel-domain proteins (occludin, tricellulin, and Mar velD3), the claudin 
family of proteins, the trispan BVES (blood vessel epicardial substance) protein, the single-span 
JAMs (junctional adhesion molecule-A, -B, and -C), and the polarity determinant Crumbs3. The 
cytoplasmic plaque is composed of Zona occludens proteins (ZO-1, ZO-2, and ZO-3), multi-
PDZ domain protein 1 (MUPP1), cingulin, protein associated with Lin-7 (PALS1), Pals1 associ-
ated tight junction (PATJ), protease activated receptor 3 (PAR3) and protease activated receptor 
6 (PAR6), which interact in the intracellular space with the cytoskeleton. Moreover, several 
signaling molecules are associated to the proteins of the cytoplasmic plaque [19].
Oclns and Cldns mainly characterize TJs. The exact role of Ocln is not well known, but it may 
be a structural component important in in the formation of TJs. Its function is regulated via 
cytokines, proteases and GTPases [20].
The Wnt/β-catenin pathway, play role in BBB differentiation and may be fundamental in BBB 
maintenance. Such a pathway is also active in endothelial cells of the adult CNS, providing an 
essential tool for BBB maintenance [21]. Claudin family member claudin-5 (Cldn5) is important 
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for TJs formation. Cldn5 is regulated by the Wnt/β-catenin pathway, however activation of VEGF, 
or other signaling pathways, can oppose the action of Wnt/β-catenin pathway. The Embryonic 
ablation of Cldn5 in mice induces early postnatal brain edema and death [21]. Claudin-5-
deficient mice exhibit an increased leakiness for small-molecular compounds (<800 Da) [22]. BBB 
leakiness can be tolerated during embryogenesis as long as the placental barrier is functional. A 
post-natal maturation of brain circulation is a more than likely fact. Indeed, in the mammalian 
brain, angiogenesis in the cortex well proceeds until 2–3 weeks after birth [23].
Interestingly, in the regions where the corners of three epithelial cells meet, TJs have a 
specialized structure, the so-called tricellular junctions (tTJs) which contain the tetraspan 
Marvel-domain protein tricellulin. Such a protein has been detected in the rat and human 
brain [24, 25]. Tricellular junctions may be critical for the BBB formation. Moreover, lipolysis-
stimulated lipoprotein receptor (LSR), a component of paracellular junctions in their three 
cell membranes meeting points, expression follows CNS angiogenesis and correlates with 
BBB formation during embryogenesis [26].
PCs are contractile cells surrounding the endothelium of capillaries and postcapillary venules, 
which are enclosed within the basal lamina of the endothelium along the vessels. They behave 
as mesenchymal multipotent stem cells giving rise to ECs or smooth muscle cells. PCs play 
an important role in the angiogenesis and in the BBB integrity. Pericytes show specialized 
characteristics and roles in different organs such as kidney, liver and brain. Moreover, density 
of pericytes and vessel coverage vary among tissues [27].
A direct contact between pericytes and ECs is established where the basement membrane is 
absent via the “peg-and-socket” junctions which are formed by n-cadherin and connexin-43 
hemichannels. Adherent junctions between PCs and ECs are also present. Interactions of ECs 
with PCs and SMCs are pivotal processes in the regularization, remodeling, stabilization and 
function of vascular wall and BBB, i.e., by the regulation of the transcellular barrier [27–29].
Moreover, the single adhesion receptor CD146 functions on PCs as a co-receptor for Platelet-
derived growth factor receptors beta (PDGFR-β) to regulate interactions between ECs and 
PCs. CD146, shows an initial expression on ECs, during BBB maturation, that slopes down 
upon PCs recruitment and BBB maturation [30]. Interestingly, astrocytic laminin induces peri-
cyte differentiation from the resting stage to the contractile stage, switching pericyte function 
from stabilizing the BBB to compromising it [31].
Astrocytes (ACs) surround microvessels and capillaries and interact with endothelial cells 
through the end-feet of their processes. ACs play critical roles in regulating cerebral blood 
flow in response to neuronal activity by relaying signals and maintain BBB function by induc-
ing barrier properties and the polarization of transporters [28]. Under steady-state conditions 
ACs promote BBB homeostasis through soluble factors such as Sonic hedgehog (Shh), retinoic 
acid (RA), glial-derived neurotrophic factor (GDNF) and angiopoietin1 (Ang-1), which inter-
act with receptors on ECs to increase junctional protein expression, raise transendothelial 
electrical resistance (TEER), and reduce permeability. Furthermore, knocking out a-dystro-
brevin (a-DB), a scaffolding protein of the astrocytic endfeet, or astrocyte-secreted laminin a2, 
leads to down-regulation of junctional proteins and a leaky BBB [32]. Interactions between 
ACs and ECs are very important not only for formation and maintenance of BBB, but also for 
astrocytic differentiation [21].
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Morphology and function of BBB are linked as shown by microscopic observation. Early 
ultrastructural studies where performed by administration of silver nitrate in the drinking 
water of rodents [33]. They showed the presence of very scarce quantity of silver around the 
capillaries in the cerebral cortex, medulla, and cerebellum. In such brain regions, capillaries 
are continuous. In other areas, such as neurohypofisis, area postrema, pineal body and inter-
columnar tubercle, heavy accumulation of silver was present around fenestrated capillaries 
[34]. Using lanthanum and horseradish peroxidase as tracers, via intravenous injection, it has 
been demonstrated that these substances are unable to penetrate between the endothelial cells 
because of the tight junctions presence (zonulae occludentes). Regarding the contribution of 
astrocytes to the BBB, it is well known that its end-feet form a relatively complete layer, but 
the junctions between are gap junctions and not of the occluding kind [35]. Perivascular end-
feet of astrocytes do not provide an effective barrier even if substances should pass through 
the endothelial cells into the brain. Indeed, after intravenous infusion of peroxidase, endo-
thelial cells show micropinocytotic vesicles containing the tracer [36]. Such a transendothelial 
cell barrier is very selective and based on carrier-mediated transports, but is not furtherly 
mechanically regulated.
Caveolae are small, bulb-shaped, plasma membrane invaginations. They have been described 
to have a function in endocytosis and transcytosis and in in maintaining the lipid composition 
of the membrane, as well as acting as signaling background.
While endothelial cells in peripheral organs, such as the lung and heart, are enriched in caveo-
lae, in BBB only a small number of caveolae are detectable [24]. Mfsd2a (transporter of the 
major facilitator superfamily domain-containing (Mfsd) family) contributes to the regulation 
of vesicular traffic in BBB endothelial cells [37] through the transport of the essential omega-3 
fatty acid docosahexaenoic acid (DHA). The expression of Mfsd2a becomes upregulated in 
ECs with the maturation of BBB. Gene ablation of Mfsd2a in mice results in BBB leakiness and 
increased vesicular traffic in ECs.
Caveolins (Cavs) are thought to play a role in the regulation of BBB function. Cavs, are a 
family of integral membrane proteins which represent both positive and negative regulators 
of intracellular signaling as scaffolding proteins that regulate the intracellular distribution 
of the signaling molecules. Cav-1 overexpression protects the integrity of the BBB mainly by 
preventing the degradation of TJ proteins in rats [38].
Cav-1 is a marker of caveolae in endothelial cells and is important in the regulation of various 
functions like endocytosis, transcytosis, signal transduction, and molecular transport. Recent 
studies on mice indicate that the suppression of the caveolae pathway requires the transport 
of lipids, notably DHA-containing phospholipids, by Mfsd2a to regulate CNS endothelial cell 
plasma membrane composition and to inhibit caveolae vesicle formation [39].
Moreover, Cav-1 regulate the angiogenic response by influencing VEGF receptor 2 (VEGFR2) 
phosphorylation and internalization [40, 41].
In BBB the basement membrane (BM) represents the noncellular component. Astrocytes, PCs 
and ECs synthetize and secrete molecules which constitute the BM surrounding the external 
surface of the endothelial cell, composed by type IV collagen, fibronectin, heparan sulfate, 
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nidogen, osteonectin and laminin. BM functions as a charge and molecular weight barrier 
and is able to interact with integrins in order to regulate permeability and cellular transport 
also across the BBB. Dystroglycans and integrins are transmembrane receptors that allow 
BBB cells to interact with BM. During brain angiogenesis in mice, ECs show α4β1 and α5β1 
integrin, whereas in adult animals α4 and α5β1integrins promote stabilization of vessels [42], 
α4β1 and α5β1 integrin induce cell proliferation through MAPK signaling in human ECs. 
Moreover, β1 integrin interaction with laminin maintains levels of claudin-5 in TJs [43, 44].
3. Blood-brain barrier damage
The endothelial cells (ECs) compose the wall of vessels and capillaries and represent the 
primary blood-tissue barrier. The ECs acting as a protective filter are able to regulate the 
passage of molecules and immune cells and the level of specialization of each blood-barrier 
is determined by the functions of endothelial-wall. In the brain, there is the higher level of 
specialization of the endothelial wall. The filter function of BBB is carried out by ECs strictly 
interconnect with numerous tight junctions.
Pathological conditions within the central nervous system like ischemia, inflammation or 
tumor growth lead to blood-brain barrier (BBB) dysfunction, emphasizing that the perme-
ability barrier regulation is principally provided by the local microenvironment and its main-
tenance is a necessary condition in any circumstance. In many brain tumors morphological 
irregularities of the perivascular space correlate with a breakdown of the BBB [45–47].
Wolburg et al. [48] found that claudin-3, a key component of BBB tight junctions, is lost in 
glioblastoma. Further evidence on claudin-1 loss in tumor microvessels, as well as downregu-
lation of claudin-5 and occludin in hyperplastic vasculature, result in a phenotypic change in 
BBB function due to leaky tight junctions and hyperpermeable endothelial cells.
A recent study by Watkins et al. [49] using a mouse model demonstrates that astrocytic end-
feet displace from their position alongside endothelial cells with disruption of the communi-
cation between the astrocytes and vasculature and that single glioma cells were sufficient to 
produce local BBB opening.
The structural perturbations of the vascular barrier during tumor progression, in other organs 
was demonstrated, are successive to the release in the tumor microenvironment of specific 
cytokines that downregulate the transcription of these structural proteins [50].
The crucial point is the vascular damage that the tumor direct and indirect operas through the 
release on the next microenvironment of chemical factors able to increase the permeability of 
the tissue vessels reducing their protective barrier function. This could explain the pathogen-
esis of the BBB damage occurring during the development of glioblastoma. The BBB damage 
induced by the glioblastoma represents a strategy employed to control the BBB opening to 
allow the passage of drugs [51].
The detection of endogenous circulating molecules normally restricted by the BBB, namely albu-
min, immunoglobulin G, or fibrinogen, in the brain parenchyma, using immunohistochemistry 
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or immunofluorescence is one of the most straightforward in situ techniques used to assess 
BBB impairment [52].
Measurement of exogenous tracer extravasation remains a technique of choice in preclinical 
studies testing for BBB permeability. A variety of detectable exogenous tracers has become 
available, and methods have been developed to evaluate the kinetics of their extravasation. 
Due to variations in tightness of the BBB, the extravasation of different BBB permeability 
tracers across an impaired BBB critically depends on their physicochemical properties and 
molecular weight.
In recent years, different in vivo imaging techniques have contributed to the understanding of 
BBB dysfunction in disease [52]. Among these, noteworthy:
• In vivo confocal microscopy, an important tool for the high-resolution dynamic fluores-
cence imaging in BBB research. This technique has the advantage of time-lapse imaging of 
the same subject. The apparent disadvantages of this technique are the technical complex-
ity and invasive nature, because it requires opening of a cranial window in experimental 
animals.
• Noninvasive fluorescence imaging (NFI), image acquisition is fast (in the range of seconds), 
and the imaging equipment is comparably inexpensive, simple, and easy to use. However, 
NFI has a limited resolution (1–2 mm) and quantitation of the imaging signal has several 
pitfalls.
• Nuclear imaging, rarely used for clinical imaging of BBB impairment. Examples of nuclear 
imaging techniques are single photon emission computed tomography (SPECT) and posi-
tron emission tomography (PET).
• Magnetic resonance imaging, MRI upon intravenous injection of a contrast agent, usually 
gadolinium-diethylene triamine pentaacetic acid (Gd-DTPA; MW 550 Da), is the most com-
monly used noninvasive imaging technique for detection of BBB impairment in both clini-
cal and preclinical studies.
With the exception of brain tumors, where angiogenic biomarkers have been targeted for 
molecular imaging [53], cerebrovascular biomarkers have not yet been fully exploited for 
molecular imaging of brain diseases.
Despite this advance the problem to track BBB opening remains for insufficient selectivity, 
specificity of the tools provided and for the no sufficiently abundancy [52] of the biologics-
based molecular imaging probes today available. In this prospective the liquid biopsy could 
represent an opportunity to track in real time the BBB opening. The concept is based on 
the causal release of tumor cells in the systemic circulation through the BBB damage. The 
structural perturbation of the BBB and the consequent modification of its permeability could 
induce cell spread independently by the molecular equipment expressed by cancer cell. In 
this direction, the detection of the circulating cancer cells in glioblastoma cases could acquire 
a specific significance related to the permeability of the BBB more than a prognostic value 
related to the dissemination phase of the disease (Figure 2).
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4. Glioblastoma’s angiogenesis
Gliomas are a heterogeneous group of neoplasms derived from glial cells that account for 
40–45% of all intracranial tumors. The most malignant type of glioma, Glioblastoma multi-
forme (GBM), account for approximately 12–15% of all intracranial neoplasms and 50–60% 
of all astrocytic tumors. In most European and North American countries, incidence is 
approximately 2–3 new cases per 100,000 people per year. Nearly 260,000 patients world-
wide are diagnosed annually with primary malignant brain cancer [54, 55]. The World Health 
Organization defines GBM as a cancer of grade IV characterized as malignant, mitotically 
active, and predisposed to cellular necrosis [56].
Untreated patients with glioblastoma multiform uniformly die within 3 months from the 
diagnosis. Treated patients with a protocol including surgical resection, radiation therapy, 
and chemotherapy, have a median survival of 14.6 months, with fewer than 25% of patients 
surviving up to 2 years and fewer than 10% up to 5 years [52, 57, 58]. Moreover, males had a 
slight preponderance over females, with a male-to-female ratio of 1.6:1. GBM may manifest 
in persons of any age, but it affects adults preferentially, with a peak incidence at 45–70 years 
[55]. Glioblastomas are tumors that display extensive morphological and molecular heteroge-
neity, and thus may reflect their origin from different population of astrocytes, and possibly 
from oligodendrocytes and ependymal cell lineages. GBM rarely metastasize outside the 
brain [59]. GBM can be classified into primary type and secondary type, according to whether 
they are generated de novo or by progression of lower-grade tumors. Histologically, primary 
and secondary glioblastomas are largely indistinguishable, but they differ in their genetic and 
epigenetic profiles [60]. GBM is a highly aggressive tumor with distinct histopathological fea-
tures, including high proliferation, necrosis and considerable neovascularization (i.e., angio-
genesis), leading to vessels that exhibit morphological abnormalities and “leakiness” [60]. It 
is generally accepted that the degree of angiogenesis is correlated to the malignancy of the 
tumor [58, 61]. GBMs are the most lethal cancer and the most vascularized brain cancer, with 
Figure 2. Vessel’s arrangement of endothelial cells acting as protective filter (A) mimics an array of warriors (B) placed to 
protect the tissues. In (A), primary human endothelial culture. Scale bar 100 μm (figure partially modified from Malara 
et al. IJC Heart & Vasculature [106]).
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the highest degree of vascular proliferation and endothelial cell hyperplasia [62]. Patients 
with high tumor microvascular densities exhibit shorter postoperative survival rates than 
patients with low microvascular densities [63, 64].
Angiogenesis and tumor cell invasion play a critical role in GBM development and growth, 
even during the earliest phases [65, 66].
Angiogenesis requires three distinct steps: (1) blood vessel breakdown, (2) degradation of the 
vessel basement membrane and the surrounding extracellular matrix (ECM), and (3) migra-
tion of endothelial cells for the formation of new blood vessels. The first step (1) in forming 
new blood vessels from existing vessels is the dissolution of aspects of native vessels [67].
Tumor angiogenesis results from a balance between pro-angiogenic factors and anti-angio-
genic factors with a shift toward angiogenic factors that stimulate uncontrolled and disor-
ganized vascular growth. These molecular factors can be secreted by cancer, endothelial, 
stromal, and blood cells and by the extracellular matrix [68].
Pro-angiogenic factors include vascular endothelial growth factor (VEGF), platelet-derived 
growth factor (PDGF), acidic fibroblast growth factor, basic fibroblast growth factor (bFGF), 
placental growth factor, angiopoietin-2 (Ang-2), and interleukins, whereas anti-angiogenic 
factors include angiostatin, endostatin, thrombospondin 1, and endothelial monocyte-activat-
ing polypeptide 2 [69, 70].
The VEGF play a major role in GBM angiogenesis by stimulating capillary sprouting from 
pre-existing vessels toward VEGF-expressing tumor cells. Tumor VEGF expression and 
angiogenesis are mainly hypoxia-driven, but can also be promoted by other vascular cyto-
kines and constitutively expressed by genetic tumor mutations [71].
Another mechanism of neo-vascularization includes the recruitment of endothelial progeni-
tor cells (EPCs) that have been proposed to originate from different sources, including bone 
marrow, the existing vasculature, or adipose tissue [72, 73].
Upon BBB injury, endothelial progenitor cells (EPC) contribute (directly or as a source and car-
rier of pro-angiogenic factors) to BBB re-endothelialization. EPC are involved to the cerebral 
angiogenesis associated with physiological conditions (i.e., activity-induced neurogenesis) or 
pathological conditions (i.e., tumor progression). In adults, there are three origins of EPC:
i. Bone marrow origin (EPC derived from bone marrow multipotent hemangioblasts 
[VEGFR2(+)VEcadherin(+)CD45(−)
ii. Mesenchymal origin SC) (CD73(+)CD90(+)CD105(+)CD34(−)CD45(−)];
iii. Tissue origin (EPC found at the sites of extensive angiogenesis but demonstrating no signs 
of hematopoietic origin, being, probably, derived from tissue multipotent cells) [73–75]
In pathological conditions, angiogenesis and vascular remodeling are usually considered as 
significant components of brain tissue repair program after injury (hypoxic, ischemic, trau-
matic, inflammatory, toxic, etc.) and the mobilization of EPC from bone marrow correlates to 
the severity of cerebral alterations [76].
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A key challenge in the field of BBB permeability is the current shortage of the knowledge on 
the most efficient way to cross BBB used by tumor cells. It has been suggested that the brain 
endothelial cells can actively participate in metastatic progression and stimulate increased 
BBB permeability.
During vasculogenesis, EPCs are mobilized from the bone marrow by increased concentra-
tions of chemokines, growth factors and other soluble factors in serum, including stromal 
cell-derived factor-1 (SDF-1), VEGF, and granulocyte-monocyte colony stimulating factor 
(GM-CSF) [77, 78].
Given the high rate of angiogenesis in glioblastomas and the lack of prognostic markers for 
anti-VEGF treatments in general, the kinetics and prognostic relevance of circulating endo-
thelial cells was assessed relatively this their potential role. It is clear that molecules with high 
pro-angiogenic potential provide the recruitment of EPC from bone marrow (VEGF, IL-8, 
IGF, etc.) [81]. Moreover, EPC provide paracrine signaling to facilitate angiogenesis [79, 80]. It 
has been suggested that quantification of CECs is useful to identify patients who might ben-
efit from anti-angiogenic treatments [81]. Batchelor et al., in a series of patients with glioblas-
toma treated with AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, found that viable 
CEC number increased when tumors escaped treatment [82]. Indeed, CECs, rare in healthy 
individuals, increase in vascular disorders and tumors due to vascular damage such as the 
GBM, in which, the VEGF is highly expressed and may mobilize endothelial precursors from 
the bone marrow [83–85]. During GBM progression, the extracellular matrix (ECM) changes 
its flexibility and structure (i.e., content of fibrillary proteins as collagen, fibronectin, etc.) 
and malignant infiltration of glioma may stimulate the development of distinct provisional 
ECM patterns. Indeed, tumor cells induce changes in ECM by secretion of growth factors and 
angiogenic factors such as VEGF, bFGF, PDGF, and TNF-α [86]. The combined release of these 
factors have a synergic effect on the mobilization of EPC [87]. Further studies are needed to 
assess the role of EPC in liquid biopsy as marker of BBB dysfunction.
5. Microenvironment in glioblastoma
Cytokines play a critical role in contributing to the complexity and lethality of glioblastoma 
characterized by diffuse invasiveness, immunosuppression, aggressive proliferation, vascular-
ization, and resistance to conventional radiotherapy and chemotherapy. Cytokines consist in 
small molecules with diverse effects depending on the microenvironment. Cytokines comprise 
glycoproteins and polypeptides that exert pro-inflammatory, anti-inflammatory or immuno-
suppressive action. In addition to the tumor cells, immune cells, extracellular matrix, blood 
vessels, the cytokines are an integral part of the network GBM tumor microenvironment-associ-
ated. Glioblastoma arises from astrocytes and their precursors, neural stem cells. The resulting 
tumor is a heterogeneous cellular population composed of both undifferentiated and differen-
tiated cells and containing subpopulations of tumor cell with different grade of tumorigenic 
property. Recently, study on GBM progression reveals a feed-forward mechanism with the 
epidermal growth factor receptor variant III (EGFRvIII) and STAT3 defined by the presence of 
cytokine receptor OSMR on the surface of non-tumorigenic and tumorigenic brain tumor cells. 
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In particular, EGFRvIII-OSMR complex signals activates STAT3, and STAT3 signals upregulates 
OSMR expression. The result is a feed-forward signaling mechanism that drives oncogenesis in 
GBM. One of principal activator of the JAK-STAT signaling pathway is IL-6. Interleukin-6 (IL-6) 
is a pleiotropic cytokine that regulates the immune response, but also plays a role in promoting 
tumor growth and survival [88, 89]. In gliomas, the level of IL-6 gene expression increases with 
the grade of malignancy. In GBM, the, amplification/overexpression of the IL-6 gene appears 
to be a common feature [90]. Array studies have reported that the number of IL-6 gene copies 
was increased in 40–50% of GBM [91, 92]. In ependymoma, with inflammatory phenotype, was 
described a constitutive activation of the IL6/STAT3 pathway and crosstalk between tumor and 
immune cells with significant increase in STAT3 and IL8 secretion in tumor microenvironment. 
Moreover, IL-6 and IL-8, EGF, and other cytokines are involved on the regulation of endothelial 
function at BBB level, with several potential outcomes: increased permeability, generation of 
relaying signaling including another cytokine(s) and soluble mediators potentiating the effects 
of another cytokine(s), modulation of efflux transporters). Even though the BBB within the 
tumor is considered “permeable,” in large parts of gliomas the BBB more closely resembles the 
intact BBB and prevents efficient passage of cancer therapeutics, such as small molecules and 
antibodies. Recently, was reported a tumor screening study that combined the detection and 
analysis of circulating tumor DNA with protein markers comprising some interleukins 
and the increase of chemokines (IL-6, IL-8) with encouraging results [93]. The big limit in the 
use of circulating tumor DNA in the screening phase of tumor disease is due to the poor speci-
ficity of this biomarker. In fact, mutated circulating DNA may be found in the peripheral blood 
of healthy subjects, it represents the genetic segments discarded during the normal prolifera-
tion of the cells in the body, for example during the hematopoiesis.
6. Circulating biomarkers of glioblastoma
The dissemination of cancer cells in the bloodstream transforms a limited disease in a sys-
temic pathology with remarkable prognostic and therapeutic complications for the patients. 
The phase of dissemination is a complex plan of action, in which, independently by type of 
tumor and its location, there are two main actors, the endothelial and the tumor cells. The 
endothelial cells compose the wall of vessels and capillaries and represent the primary blood-
tissue barrier. The adhesion molecules expressed on ECs surface condition the permeability 
and trans-endothelial resistance to cell crossing [6].
In the brain, the filter function of BBB is carried out by ECs strictly interconnect with numer-
ous tight junctions. The tight junctions give continuity to the endothelial wall eliminating the 
intercellular space. Astrocyte end-feet, pericytes and microglia interacting with ECs draining 
fluids in the glymphatic system. Glymphatic system controls the levels of concentration of 
solutes in the neuronal interstitium and it is connected with the blood circulation [6].
Animal models combined with observations on humans, are still promising tools in order to 
clarify mechanisms of passage of malignant cells trough the BBB. Indeed, similarly to what 
is observed in epithelial tumors have been demonstrated by patient-derived GBM xenografts 
that acquisition of a mesenchymal phenotype is mandatory for malignant cells in order to 
enter the blood stream and behavior as CTCs [94].
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The detection of CTCs in the field of CNS represents a promising noninvasive technique to 
facilitate early diagnosis and monitoring tumor evolution [95, 96]. The significance of the CTCs 
detection in intracranial tumors, commonly related to metastatic phase of the cancer disease, 
was hardly applied for the very few case with extracranial metastases observed although the 
high malignancy and invasiveness of glioma [97]. More recently, it was reported that dissemi-
nating cells of medulloblastoma were able to infiltrate the leptomeninges through hemato-
logical way [98]. Garzia et al. described an in vivo experiment consisting in via surgical union 
of two mice by their flanks. The cancer cells of medulloblastoma implanted in one mouse 
model were able via hematological to give leptomeningeal metastatic disease in the other one 
mouse. The surgical union shared not only the cells but also the biochemical environment. 
The biochemical composition of cancer microenvironment consists by a mixture of permeabi-
lizing and inflammatory cytokines. Many types of cytokines like Histamine, TNFa, IL1b and 
in particular the axis, chemokine CCL2-CCR2 receptor, sustain BBB alterations. Their action 
plays on BBB by activating cytoskeleton redistribution, downregulating structural proteins 
and favoring the tight-junction opening [99]. Garzia et al. to obtain leptomeningeal relapsing 
lesion used an experiment that shared the microenvironment rather than to inject only cancer 
cells. The tumor cells, although expressing molecular equipment involved in cell movement, 
were not able, alone, to determine leptomeningeal metastasis. The tumor cytokines mediated 
BBB-opening and successively favored cellular BBB-crossing.
Moreover, due to the contribution of other studies demonstrating that CTCs can be detected 
in all pathological subtypes of glioma, irrespective of different malignant degree, now, the 
reductive misconception of metastatic CTCs has been challenged suggesting that CTCs should 
be considered a common property of glioma lesions [100]. The behavior of the CTCs suggest 
that the pathogenesis of their release in the blood stream is independent from the grade of 
malignancy of intracranial tumor, and such as happened in other tumor diseases, this phe-
nomenon happened in each phase of cancer development [101].
The BBB confers to intracranial tumor diseases a different nosology. The presence of CTCs in 
the bloodstream of patients with intracranial tumors acquires a diverse significance respect to 
cancers located in extra-cranial sites. Regarding the intracranial cancers could be more appro-
priate to use CTCs as biomarkers of BBB-damage rather than biomarkers of a preferential/
alternative dissemination way. The understanding of this scenario is important to focus the 
better targeting strategy. The interference on the interaction between cancer-endothelial cells 
or the reduction of the cytokines levels could be the key targets for pharmacological interven-
tions for the inhibition of cell spread by an intracranial tumor.
Another emerging role in the study of glioblastoma and liquid biopsy are represented by 
the detection in the peripheral blood of extracellular vesicles (EVs) of tumor origin. EVs are 
secreted by tumor cells, are mediators of intercellular communication that transfer nucleic 
acids, proteins and lipids. The liquid biopsy of EVs in patients with GBM has the role to 
clarify their implications in tumor progression, as a tumor biomarker for tracking GBM pro-
gression and as a potential therapeutic target/delivery system [102]. Therapeutic experimen-
tal protocols involving EVs delivery of miRNA were performed for GBM. The deletions on 
chromosome 10 are a common chromosomal alteration found within GBM with leads to a 
loss of miR-146b normally located at 10q24 [103]. In GBM the loss of miR-146b facilitates 
migration and invasion. Moreover, in a study using an in vivo model, the exosomes derived 
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from marrow cells were administered in intracranial rat tumors with consequent reduction 
of glioma cell invasion, migration, viability and expression of EGFR normally amplified in 
approximately 40% of all GBM [104]. The possibility of miRNA-based approaches using exo-
somes have a strong therapeutic potential, which could be achieved through the delivery and 
transfer agents in those cases of GBM in which the BBB opening is a rare event. In these cases, 
the liquid biopsy negative for the detection of EPC and CTCs could be useful to select the 
patients eligible to this type of approach (Figure 3).
7. Conclusive remarks
In conclusion, the answers to the question when and why the liquid biopsy is useful in glio-
blastoma disease, could be different in function of the phase of disease:
1. Diagnostic glioblastoma phase: the liquid biopsy, searching and characterizing the circu-
lating glial cells, could discriminate between glioblastoma and other intracranial lesions, 
supporting the clinical imaging investigations and in substitution of the stereotactic biopsy 
procedure when this procedure is at high risk of side effects.
2. Prognostic evaluation and monitoring phase: the prognostic value of the CTCs in glioblastoma 
patients should be clarified by further studies. Their release in the bloodstream not should be 
considered as a marker of dissemination and consequently of a bad prognosis. Their detec-
tion in the blood is in function of the particular anatomic location of cancer inducing local 
structural perturbations and only partially dependent by its grade of malignancy. In fact, the 
release of CTCs in the blood is conditioned by many local factors such as peritumor inflam-
mation reaction, structural changes on the BBB, altered cancer microenvironment, etc. On this 
way, could be better to analyze the circulating segments of tumor DNA, carrying of hotspot 
mutations specifically related to glioblastoma, to define prognosis and to monitor during the 
treatment the emergence of aberrant mutations in advance to predict chemo resistance.
3. Anticancer-treatment design phase: the combining detection of CTCs and EPCs as markers 
of the opening status of BBB could be useful to individuate the better timing of treatment, 
Figure 3. Schematic representations of endothelial-cancer cells interaction. (A) Interstitium space at brain (blood-brain 
barrier, BBB) and at blood barrier (BB) of other organs. Vessels (red), pericyte (green-cell), astrocyte end-feet (yellow-cell) 
and cancer cells (blue cells). (B) Cancer cells cross BB through pre-existing inter-endothelial spaces, (C) while at BBB 
overcome the absence of intercellular spaces realizing permeabilizing cytokines (green balls).
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in which therapeutic drugs may be favorite to cross BBB. Moreover, those patients in which 
the BBB opening is not detectable through liquid biopsy could be considered a different 
therapeutic approach using EVs.
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